Investment analysts at Lifesci Capital boosted their Q1 2025 earnings per share estimates for shares of Corbus ...

Corbus Pharmaceuticals Highlights Data From Its First US-Based Trial Of Lead Cancer Drug Candidate Corbus Pharmaceuticals presented Phase 1 data on CRB-701 at ASCO GU, showing safety, tolerability ...

Corbus Pharmaceuticals Holdings, Inc. (NASDAQ:CRBP – Free Report) – Equities research analysts at HC Wainwright ... up from their previous forecast of ($1.33). HC Wainwright has a “Buy ...

Jefferies lowered the firm’s price target on Corbus Pharmaceuticals (CRBP) to $53 from $70 and keeps a Buy rating on the shares. The firm’s ...

Analyst Price Forecast Suggests 690.09% Upside As of February 19, 2025, the average one-year price target for Corbus Pharmaceuticals Holdings is $57.91/share. The forecasts range from a low of $35 ...

There’s a lot to be optimistic about in the Healthcare sector as 2 analysts just weighed in on Prelude Therapeutics (PRLD – Research Report) ...

Corbus Pharmaceuticals Holdings, Inc. is an oncology company, which engages in research, development, and commercializing therapeutics for cancer and obesity. Its pipeline includes CRB-701 ...

This was the stock's fourth consecutive day of losses.

Jan. 28, 2025 (GLOBE NEWSWIRE) -- Corbus Pharmaceuticals Holdings ... NY Dr. Cohen will participate in analyst led fireside discussion and will attend one-on-one investor meetings.

The stock's fall snapped a two-day winning streak.

These forward-looking statements are based on current expectations, estimates, forecasts and projections about the industry and markets in which we operate and management's current beliefs and ...